The pharmacological activity of derivatives of 4-oxo-3,4-dihydroquinazoline and anthranilamides containing a fragment of glycine

Yu. O. Ovsjanykova, D. V. Levashov, V. M. Kravchenko, V. P. Chernykh, L. A. Shemchuk

Abstract


Derivatives of 4-oxo-3,4-dihydroquinazoline are known as a promising class of compounds due to their wide spectrum of the pharmacological activity. Taking into account the PASS data for the substituted anthranilamides synthesized, as well as derivatives of 4-oxo-3,4-dihydroquinazoline containing an “in-built” fragment of amino acid glycine as a pharmacophore, the decision to study their central neurotropic effects was made. While studying the hypnotic, anticonvulsant and antidepressant activities the highest antidepressant properties of N-(1,1-diphenyl-1-hydroxyet-2-yl)-N'-diphenylhydroxyacetylanthranilamide (compound 4) have been determined, this compound is slightly inferior the reference drug Imipramine. N-(phenylhydrazidoacetyl)-N'-succinamidoanthranilamide (compound 1) reveals high anticonvulsant properties and is not inferior the classical anticonvulsant drug Depakine. When studying the hypnotic effect the antagonism with Barbamyl for 2-(4-oxo-3,4-dihydro-3-quinazolinyl)acetohydrazide (compound 5) has been found. Methyl-(2-methylcarbonyloxymethyl-4-oxo-3,4-dihydro-3-quinazolinyl)acetate (compound 8) decreased the latent period of “falling asleep” for animals in 1.6 and 1.7 times in the doses of 20 and 200 mg/kg, respectively (the same level with the reference drug), and therefore, it is a promising compound for further research of the hypnotic activity. The analysis of the “structure-activity” relationship gives the possibility to assume that such pronounced pharmacological activity is due to the presence of substituents in position 2 of the quinazoline nucleus. Therefore, the data obtained prove that the study of these derivatives is promising for further search of new biologically active substances with hypnotic, anticonvulsant and antidepressant properties.

Keywords


quinazolone; anthranilamide; antidepressant effect; anticonvulsant activity; hypnotic activity

Full Text:

PDF

References


Головенко М.Я., Громов Л.О. Доклінічне вивчення специфічної активності потенційних проти судомних препаратів: Метод. рекоменд. – К.: Авіценна, 2003. – 26 с.

Миронов А.Н., Кукес В.Г. Руководство по проведению доклинических исследований лекарственных средств. Ч. I. – М.: Гриф и К, 2012. – 244 с.

Manoj K., Srivastava S., Bharati M., Nizamuddin N. // Ind. J. Chem. – 2001. – Vol. 40. – P. 342-344.

Perumal P., Bilal A.R., Dontireddy R.S.R., Natesh R.K. // Eur. J. of Med. Chemistry. – 2009. – Vol. 44. – P. 2328-2333.

Porsolt R.D., Lenegre A., Elliot J.M. et al. // Experimental Approaches to Anxiety and Depression. – Chichester New York, 1992. – P. 73-85.

Sarvesh K.P., Abhishek S., Ashutosh S. // Eur. J. Med. Chem. – 2009. – Vol. 44. – P. 1188-1197.

Shemchuk L.A., Al-Asri Jamil M., Levashov D.V. et al. // Вісник Фармації. – 2011. – №3. – С. 30-32.

Shemchuk L.A., Levashov D.V., Al-Asri Jamil M. et al. // ЖОФХ. – 2011. – Т. 8, №9. – С. 36-39.

Shisokoo J., Shirsath S., Rathod J.S., Yande O. // Eur. J. Med. Chem. – 2000. – Vol. 35. – №3. – P. 351-358.

Usifoh C.O., Scriba K.E. // Med. Chem. – 2000. – Vol. 333. – P. 261-266.


GOST Style Citations






DOI: https://doi.org/10.24959/88860

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)